MyriaMeat

What MyriaMeat does

MyriaMeat GmbH is a German biotech startup founded in 2023 that develops 100% cell-cultivated meat using cellular agriculture. The company takes cells from animals, creates proprietary cell-lines from induced pluripotent stem cells (iPSCs), and cultivates tissue-engineered muscle in bioreactors without scaffolds, plant-based blends, or genetic modification. It is headquartered in Munich (Nussbaumstraße 10) with research and laboratory operations in Göttingen (Rudolf-Wissel-Straße 28a). The product portfolio to date includes a 100% muscle cultivated pork fillet (June 2024) and a hybrid bratwurst prototype combining 20% cultured meat with conventional pork, developed jointly with Hans Kupfer & Sohn. Pipeline references include cultivated Wagyu beef, deer meat, and fish. The company states its products are 100% real muscle tissue, free from antibiotics, E. coli, and prions, and projects a 50%–90%+ reduction in environmental impact across land, water, and energy use versus conventional meat.

The underlying technology rests on patented production methods for deriving species-specific cell-lines and growing functional muscle tissue in controlled bioreactor environments. Co-founders Dr. Malte Tiburcy (Head of Research at the University of Göttingen) and Prof. Dr. Wolfram-Hubertus Zimmermann (Director of the Institute for Pharmacology and Toxicology at Universitätsmedizin Göttingen) anchor the scientific platform. Strategic ecosystem relationships include Sartorius AG for bioreactor equipment and scale-up, the University of Göttingen for research infrastructure, SPRIND (Bundesagentur für Sprunginnovationen) for showcasing breakthroughs, and Hans Kupfer & Sohn for industrial co-development. Public-sector support comes from the European Regional Development Fund (EFRE) and the Lower Saxony state program (SER); no institutional equity investors are disclosed.

The business model is B2B-only and explicitly pre-commercial. Terms & Conditions restrict sales to corporate customers under German Civil Code §14 and exclude consumers under §13. There is no public pricing, no commercial product on the market, and no disclosed revenue — commercialization depends on EU Novel Food regulatory approval, which is still pending for all cultivated-meat offerings. Until approval, the company is best understood as a grant- and partnership-funded R&D venture building toward hybrid (transitional) products and, eventually, fully cultivated meat in collaboration with established meat processors.

Name

MyriaMeat

Legal name

MyriaMeat GmbH

Website

https://myriameat.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

MyriaMeat is a German biotech startup that produces 100% cell-cultivated meat from pluripotent stem cells via cellular agriculture, targeting B2B food-industry and meat-processing customers with products pending EU regulatory approval.

Ownership category

akta.pro rank

Product category

Cultivated Meat / Cellular Agriculture

NAICS

Animal Slaughtering and Processing (3116)

SIC

Miscellaneous Food Preparations & Kindred Products (2090), Sausages & Other Prepared Meat Products (2013)

akta.pro primary industry

Cultivated Meat Producers (Cell-Cultured Meat & Seafood) (AFANAKAC)

akta.pro secondary industries

Cultivated (Cell-Based) Protein Foods Manufacturing (AFAKAGAI), Cell Line Development & Banking (Food/AG Cell Lines) (AFANAKAE), Finished Meat-Alternative Prepared Foods (Nuggets, Burgers, Sausages, Ready Meals) (AFANAKAO)

Keywords

• Cultivated meat production
• Cellular agriculture technology
• Tissue engineered muscle
• Cell-cultivated pork
• Alternative protein biotech

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cultivated Meat Products: Pre-revenue stage. The company is developing cultivated meat products including Wagyu beef, pork, and deer meat. Products are not yet commercially available pending EU regulatory approval.
2. Research and Development Grants: Funded through European Regional Development Fund (ERDF) and Lower Saxony state programs. R&D collaborations with industrial partners on hybrid meat products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

MyriaMeat produces 100% real cultivated meat by taking animal cells, creating species-specific cell-lines from pluripotent stem cells (iPSCs), and growing functional muscle tissue inside bioreactors without slaughter, genetic modification, or plant-based scaffolds. The portfolio centers on a 100% muscle cultivated pork fillet and a hybrid bratwurst prototype (20% cultured meat / 80% conventional pork) co-developed with industrial meat processors, with planned extensions to Wagyu beef, deer, and fish. Products are sold B2B to corporate food-industry customers pending EU regulatory approval.

Product overview

MyriaMeat is a biotech startup producing 100% real cultivated meat through cellular agriculture using pluripotent stem cells. The core product is cell-based muscle tissue that is identical to conventional animal meat without slaughter, antibiotics, or plant-based fillers. The portfolio includes the Muscle Cultivated Pork Fillet (world's first), Hybrid Bratwurst (20% cultured meat prototype with Hans Kupfer), and planned cultivated Wagyu beef, pork, deer, and fish products. The company uses patented, scalable bioreactor technology and is developing hybrid products as a transitional step toward full cultivated meat commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Muscle Cultivated Pork Fillet A 100% muscle cultivated pork fillet produced entirely from pig cells via pluripotent-stem-cell (iPSC) tissue engineering, with no scaffolds and no added plant-protein blends for shape. Sold B2B to corporate food-industry customers; commercial launch pending EU regulatory approval.
• Hybrid Bratwurst Prototype A hybrid bratwurst prototype combining 20% MyriaMeat cultured meat (functional muscle tissue) with 80% conventional pork, developed jointly with industrial partner Hans Kupfer & Sohn. Targeted at meat-processing and food-industry customers pursuing reduced ecological footprint without sacrificing traditional sausage quality; commercialization subject to EU regulatory approval.

Quantifiable outcome

• 50-90%+ reduction in environmental impact (land use, water use, energy use)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Hans Kupfer & Sohn GmbH & Co. KGcoreStrategic or Co-development Partner · 1 October 2025Joint research and development project to develop hybrid bratwurst sausages containing 20% cultured meat. Kupfer provides industrial expertise and technical center for handcrafting prototypes. The collaboration combines conventional pork with MyriaMeat's cell-cultured muscle tissue. Project funded by ERDF and Lower Saxony.
• Sartorius AGcoreTechnology or Integration · 22 October 2023MyriaMeat team visited Sartorius application center in Göttingen to explore bio-reactor technology necessary for future scale-up factory. Sartorius provides bioreactor equipment and expertise for cell cultivation.
• University of GöttingencoreStrategic or Co-development PartnerCo-founder Dr. Malte Tiburcy serves as Head of Research at the University of Göttingen. Prof. Dr. Wolfram-Hubertus Zimmermann, Director of the Institute for Pharmacology and Toxicology, is co-founder. University provides scientific research infrastructure and expertise in pluripotent stem cells.
• SPRIND (Bundesagentur für Sprunginnovationen)minorStrategic or Co-development PartnerPresented world-first pork product at SPRIND event in Berlin. SPRIND is the Federal Agency for Breakthrough Innovation supporting transformative technologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Upside Foods: US cultivated meat leader (formerly Memphis Meats) producing cell-cultured chicken, beef, and duck. Direct peer on cultivated meat technology, B2B enterprise sales motion, and pursuit of regulatory approval for cell-cultured proteins.
• SuperMeat: Israeli cultivated chicken company using cellular agriculture similar to MyriaMeat's approach. Comparable on the cellular agriculture platform and on B2B enterprise GTM motion to meat producers and food service operators.
• Mosa Meat: Dutch cultivated meat pioneer developing cell-cultured beef using similar bovine stem cell approaches. Closely comparable to MyriaMeat on technology (cellular agriculture, iPSC- or satellite-cell-derived muscle), category (cultivated beef), and geography (EU regulatory pathway).
• Eat Just (GOOD Meat): US-based cultivated meat division of Eat Just, first company to receive regulatory approval for cultivated meat (Singapore, US). Direct competitor on cell-cultured meat technology and regulatory pathway, though with significantly larger scale and funding.
• Aleph Farms: Israeli cultivated meat company producing cell-grown beef steaks including premium cuts like ribeye and thin-cut steak. Comparable to MyriaMeat on cultivated beef ambition, multi-species approach, and premium positioning.
• Future Meat Technologies: Israeli cultivated meat company producing cell-grown chicken, beef, and lamb using proprietary non-GMO technology. Comparable on cultivated meat core technology and multi-species portfolio, with more advanced commercial pilots.

Emerging players

• Finless Foods: US cultivated seafood company producing cell-cultured tuna and other marine species. Comparable on cellular agriculture technology applied to fish protein, relevant to MyriaMeat's stated fish product roadmap.
• Wildtype: US cultivated salmon company using cellular agriculture to produce sushi-grade salmon. Comparable to MyriaMeat's planned fish product line on cell culture technology and premium positioning for aquaculture substitute.
• Bluenalu: US-based cultivated seafood company producing cell-cultured fish and shellfish. Comparable to MyriaMeat's planned cultivated fish expansion into aquaculture-adjacent categories using similar cell culture technology.

Regional players

• Vital Meat: French cultivated meat subsidiary of Gourmy, focused on cell-cultured meat for the European market. Most direct EU regional peer to MyriaMeat, sharing the same EU regulatory pathway and continental customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@MyriaMeat
• LinkedInlinkedin.com/company/myriameat

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MyriaMeat